|
1
|
Domingues P, González-Tablas M, Otero Á,
Pascual D, Ruiz L, Miranda D, Sousa P, Gonçalves JM, Lopes MC,
Orfao A and Tabernero MD: Genetic/molecular alterations of
meningiomas and the signaling pathways targeted. Oncotarget.
6:10671–10688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pećina-Šlaus N, Nikuseva Martic T, Tomas
D, Beros V, Zeljko M and Cupic H: Meningiomas exhibit loss of
heterozygosity of the APC gene. J Neurooncol. 87:63–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Habr EA, Levidou G, Trigka EA,
Sakalidou J, Piperi C, Chatziandreou I, Spyropoulou A, Soldatos R,
Tomara G, Petraki K, et al: Complex interactions between the
components of the PI3K/AKT/mTOR pathway, and with components of
MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in
meningioma development. Virchows Arch. 465:473–485. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Khalaf HH, Lach B, Allam A, Lakhani A,
Alrokayan SA and Aboussekhra A: The p53/p21 DNA damage-signaling
pathway is defective in most meningioma cells. J Neurooncol.
83:9–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sorrell AD, Espenschied CR, Culver JO and
Weitzel JN: Tumor protein p53 (TP53) testing and Li-Fraumeni
syndrome: Current status of clinical applications and future
directions. Mol Diagn Ther. 17:31–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohgaki H, Eibl RH, Schwab M, Reichel MB,
Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD and Kleihues
P: Mutations of the p53 tumor suppressor gene in neoplasms of the
human nervous system. Mol Carcinog. 8:74–80. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ellison DW, Lunec J, Gallagher PJ, Steart
PV, Jaros E and Gatter KC: Accumulation of wild-type p53 in
meningiomas. Neuropathol Appl Neurobiol. 21:136–142. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joachim T, Ram Z, Rappaport ZH, Simon M,
Schramm J, Wiestler OD and von Deimling A: Comparative analysis of
the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and
radiation-induced human meningiomas. Int J Cancer. 94:218–221.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Das A, Tan WL and Smith DR: p53 point
mutation is rare in meningiomas from Singaporean patients. Asian J
Surg. 28:7–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pykett MJ, Landers J and George DL:
Expression patterns of the p53 tumor suppressor gene and the mdm2
proto-oncogene in human meningiomas. J Neurooncol. 32:39–44. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho H, Ha SY, Park SH, Park K and Chae YS:
Role of p53 gene mutation in tumor aggressiveness of intracranial
meningiomas. J Korean Med Sci. 14:199–205. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang JL, Zhang ZJ, Hartman M, Smits A,
Westermark B, Muhr C and Nistér M: Detection of TP53 gene mutation
in human meningiomas: A study using immunohistochemistry,
polymerase chain reaction/single-strand conformation polymorphism
and DNA sequencing techniques on paraffin-embedded samples. Int J
Cancer. 64:223–228. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohkoudo M, Sawa H, Hara M, Saruta K, Aiso
T, Ohki R, Yamamoto H, Maemura E, Shiina Y, Fujii M and Saito I:
Expression of p53, MDM2 protein and Ki-67 antigen in recurrent
meningiomas. J Neurooncol. 38:41–49. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amatya VJ, Takeshima Y and Inai K:
Methylation of p14(ARF) gene in meningiomas and its correlation to
the p53 expression and mutation. Mod Pathol. 17:705–710. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang Z, Guo CL, Ahronowitz I,
Stemmer-Rachamimov AO, MacCollin M and Nunes FP: A role for the p53
pathway in the pathology of meningiomas with NF2 loss. J
Neurooncol. 91:265–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Gejman R, Mahta A, Zhong Y, Rice
KA, Zhou Y, Cheunsuchon P, Louis DN and Klibanski A: Maternally
expressed gene 3, an imprinted noncoding RNA gene, is associated
with meningioma pathogenesis and progression. Cancer Res.
70:2350–2358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marcel V, Nguyen Van Long F and Diaz JJ:
40 years of research put p53 in translation. Cancers (Basel).
10:E1522018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riemenschneider MJ, Perry A and
Reifenberger G: Histological classification and molecular genetics
of meningiomas. Lancet Neurol. 5:1045–1054. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fathi AR and Roelcke U: Meningioma. Curr
Neurol Neurosci Rep. 13:3372013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He S, Pham MH, Pease M, Zada G, Giannotta
SL, Wang K and Mack WJ: A review of epigenetic and gene expression
alterations associated with intracranial meningiomas. Neurosurg
Focus. 35:E52013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pavelin S, Becic K, Forempoher G, Mrklic
I, Pogorelic Z, Titlic M and Andelinovic S: Expression of Ki-67 and
p53 in meningiomas. Neoplasma. 60:480–485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Narla S, Uppin MS, Saradhi MV, Sahu BP,
Purohit AK and Sundaram C: Assessment of expression of epidermal
growth factor receptor and p53 in meningiomas. Neurol India.
62:37–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trott G, Pereira-Lima JF, Leães CG,
Ferreira NP, Barbosa-Coutinho LM and Oliveira MC: Abundant
immunohistochemical expression of dopamine D2 receptor and p53
protein in meningiomas: Follow-up, relation to gender, age, tumor
grade, and recurrence. Braz J Med Biol Res. 48:415–419. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Preusser M, Brastianos PK and Mawrin C:
Advances in meningioma genetics: Novel therapeutic opportunities.
Nat Rev Neurol. 14:106–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang N and Osswald M: Meningiomas:
Overview and new directions in therapy. Semin Neurol. 38:112–120.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pereira BJA, Oba-Shinjo SM, de Almeida AN
and Marie SKN: Molecular alterations in meningiomas: Literature
review. Clin Neurol Neurosurg. 176:89–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pećina-Šlaus N: Merlin the NF2 gene
product. Pathol Oncol Res. 19:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pećina-Šlaus N, Kafka A and Lechpammer M:
Molecular genetics of intracranial meningiomas with emphasis on
canonical Wnt signalling. Cancers (Basel). 8:E672016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adzhubei IA, Schmidt S, Peshkin L,
Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A
method and server for predicting damaging missense mutations. Nat
Methods. 7:248–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sim NL, Kumar P, Hu J, Henikoff S,
Schneider G and Ng PC: SIFT web server: Predicting effects of amino
acid substitutions on proteins. Nucleic Acids Res. 40((Web Server
Issue)): W452–W457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schwarz JM, Cooper DN, Schuelke M and
Seelow D: MutationTaster2: Mutation prediction for the
deep-sequencing age. Nat Methods. 11:361–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Olivier M, Langerød A, Carrieri P, Bergh
J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche
I, et al: The clinical value of somatic TP53 gene mutations in
1,794 patients with breast cancer. Clin Cancer Res. 12:1157–1167.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lindenbergh-van der Plas M, Brakenhoff RH,
Kuik DJ, Buijze M, Bloemena E, Snijders PJ, Leemans CR and
Braakhuis BJ: Prognostic significance of truncating TP53 mutations
in head and neck squamous cell carcinoma. Clin Cancer Res.
17:3733–3741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Omura G, Ando M, Ebihara Y, Saito Y,
Kobayashi K, Fukuoka O, Akashi K, Yoshida M, Asakage T and Yamasoba
T: The prognostic value of TP53 mutations in hypopharyngeal
squamous cell carcinoma. BMC Cancer. 17:8982017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 variations in human
cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Walerych D, Lisek K and Del Sal G: Mutant
p53: One, no one, and one hundred thousand. Front Oncol. 5:2892015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Harms KL and Chen X: The functional
domains in p53 family proteins exhibit both common and distinct
properties. Cell Death Differ. 13:890–897. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Verheijen FM, Sprong M, Kloosterman JM,
Blaauw G, Thijssen JH and Blankenstein MA: TP53 mutations in human
meningiomas. Int J Biol Markers. 17:42–48. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Faria MH, Neves Filho EH, Alves MK,
Burbano RM, de Moraes Filho MO and Rabenhorst SH: TP53 mutations in
astrocytic gliomas: An association with histological grade, TP53
codon 72 polymorphism and p53 expression. APMIS. 120:882–889. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grochola LF, Zeron-Medina J, Mériaux S and
Bond GL: Single-nucleotide polymorphisms in the p53 signaling
pathway. Cold Spring Harb Perspect Biol. 2:a0010322010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Naccarati A, Polakova V, Pardini B,
Vodickova L, Hemminki K, Kumar R and Vodicka P: Mutations and
polymorphisms in TP53 gene-an overview on the role in colorectal
cancer. Mutagenesis. 27:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Choy W, Kim W, Nagasawa D, Stramotas S,
Yew A, Gopen Q, Parsa AT and Yang I: The molecular genetics and
tumor pathogenesis of meningiomas and the future directions of
meningioma treatments. Neurosurg Focus. 30:E62011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Terzi A, Saglam EA, Barak A and
Soylemezoglu F: The significance of immunohistochemical expression
of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol
Res Pract. 204:305–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Boström J, Meyer-Puttlitz B, Wolter M,
Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP and
Reifenberger G: Alterations of the tumor suppressor genes CDKN2A
(p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C
(p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol.
159:661–669. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mashiyama S, Murakami Y, Yoshimoto T,
Sekiya T and Hayashi K: Detection of p53 gene mutations in human
brain tumors by single-strand conformation polymorphism analysis of
polymerase chain reaction products. Oncogene. 6:1313–1318.
1991.PubMed/NCBI
|
|
50
|
Matsuno A, Nagashima T, Matsuura R, Tanaka
H, Hirakawa M, Murakami M, Tamura A and Kirino T: Correlation
between MIB-1 staining index and the immunoreactivity of p53
protein in recurrent and non-recurrent meningiomas. Am J Clin
Pathol. 106:776–781. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nagashima G, Aoyagi M, Yamamoto M,
Yamamoto S, Wakimoto H, Ohno K, Yamamoto K and Hirakawa K: P53
overexpression and proliferative potential in malignant
meningiomas. Acta Neurochir (Wien). 141:53–61. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ozen O, Demirhan B and Altinörs N:
Correlation between histological grade and MIB-1 and p53
immunoreactivity in meningiomas. Clin Neuropathol. 24:219–224.
2005.PubMed/NCBI
|
|
53
|
Karamitopoulou E, Perentes E, Tolnay M and
Probst A: Prognostic significance of MIB-1, p53, and bcl-2
immunoreactivity in meningiomas. Hum Pathol. 29:140–145. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Csonka T, Murnyák B, Szepesi R, Kurucz A,
Klekner Á and Hortobágyi T: Poly(ADP-ribose) polymerase-1 (PARP1)
and p53 labelling index correlates with tumour grade in
meningiomas. Folia Neuropathol. 52:111–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pećina-Šlaus N, Kafka A, Vladušić T, Tomas
D, Logara M, Skoko J and Hrašćan R: Loss of p53 expression is
accompanied with upregulation of beta-catenin in meningiomas: A
concomitant reciprocal expression. Int J Exp Pathol. 97:159–169.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Leroy B, Fournier JL, Ishioka C, Monti P,
Inga A, Fronza G and Soussi T: The TP53 website: An integrative
resource centre for the TP53 mutation database and TP53 mutant
analysis. Nucleic Acids Res. 41((Database Issue)): D962–D969. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Marcel V and Hainaut P: p53 isoforms-a
conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life
Sci. 66:391–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Feng Z, Hu W, Teresky AK, Hernando E,
Cordon-Cardo C and Levine AJ: Declining p53 function in the aging
process: A possible mechanism for the increased tumor incidence in
older populations. Proc Natl Acad Sci USA. 104:16633–16638. 2007.
View Article : Google Scholar : PubMed/NCBI
|
